ing. It is shown to what extent HTA, HNA and HIA contribute to translational research by using the continuum of translational research (T1-T4) in genomic medicine as an analytic framework. The selected assessment methodologies predominantly cover 2 to 4 phases within the T1-T4 system. HTA delivers the most complete set of methodologies when assessing health applications. HNA can be used to prioritize areas where genomic health applications are needed or to identify infrastructural needs. HIA delivers information on the impact of technologies in a wider scope and promotes informed decision making. HTA, HNA and HIA provide a partly overlapping and partly unique set of methodologies and infrastructure for the translation and assessment of genomic health applications. They are broad in scope and go beyond the continuum of T1-T4 translational research regarding policy translation.
Background
In 2007 the European Commission (EC) launched its health strategy 'Together for Health' on which the work from 2008-2013 should be based. In the health strategy core principles like 'Health is the greatest Wealth' and 'Health in all Policies' are proposed which should underpin the strategic objectives. One of the strategic objectives is aimed at 'supporting dynamic health systems and new technologies' to ensure a competitive and sustainable future for Europe: E-health, biotechnology and genomics are expected to improve prevention of illness and delivery of treatment and to support a shift from hospital care to prevention and primary care [1] .
The Human Genome Project has already led to numerous discoveries, and the number of genomic discoveries is expected to increase further [2, 3] . In addition, disciplines like Human Genome Epidemiology (HuGE) aim to identify genome-based health information of public health relevance by analysing the impact of genomic variants on the risk of developing diseases or disabilities and to measure how this and other risk factors (e.g. lifestyle or environment) interact [4, 5] . However, despite the promising nature of genomics and its potential to improve population health, the actual translation from basic research to the bedside and to health promotion campaigns for the general public has been slow. In addition, the European Commission explicitly recognises in its health strategy that technologies must be properly evaluated before widespread use or inclusion in public health policies can be warranted. This article addresses these two considerations, namely, the huge number of novel discoveries and the associated need for assessment. More specifically, the use of traditional public health assessment instruments for translational research in genomic medicine is investigated. The paper is based on results of the Public Health Genomics European Network (PHGEN) -a project which was funded by the European Commission from [2005] [2006] [2007] [2008] . But before elaborating, some background information and definitions from the field of genomics will be provided as well as an introduction to the concept of translational research.
Given the range of genomic technologies that are relevant to public health genomics, this paper focuses on predictive, diagnostic, susceptibility, and screening applications which contribute to health information in a wider genomic context and on pharmacogenomical technologies. Translational research, as it is meant in this paper, refers to 'translating research into practice; i.e., ensuring that new treatments and research knowledge actually reach the patients or populations for whom they are intended and are implemented correctly' [6] .
In the field of genomics, translational research is of utmost importance, since the vast majority of potential applications are either still in the phase of basic research or are being provided directly to consumers, without involvement of health care providers or independent assessment [7] [8] [9] . The definition of public health genomics emphasises the need for a 'responsible and effective translation of genome-based knowledge and technologies for the benefit of population health' [10] . The framework of the 'Public Health Genomics Enterprise' stresses the challenge of knowledge translation by defining the first and central task of public health genomics as 'knowledge integration within and across disciplines' [10] . It is the driving force for public health genomics (PHG) by which information is transformed into useful knowledge [10] .
The steps which are necessary to translate genomic discoveries into health care and disease prevention have been defined by Khoury et al. [4] . They applied the 'continuum of translational research' to the context of genome-based health applications and defined 4 phases of translational research (T1-T4):
T1 -From gene discovery to candidate health application: This phase starts after new, promising discoveries in the field of genomics are made. Whether these discoveries can be transformed into useful applications for clinical and public health practice has to be assessed. This can be done by observational research and clinical trials taking evaluation criteria like ACCE into account (ACCE components: analytical validity, clinical validity, clinical utility, including the legitimacy, efficacy, effectiveness, and appropriateness of a technology as well as its ethical, legal and social implications [11] ).
T2 -From health application to evidence-based practice guideline: Translational research in phase 2 has to perform the task of assessing the value of a genomic application for health practice leading to the development of evidence-based guidelines.
T3 -From evidence-based guidelines to health practice: T3 aims to integrate evidence-based guidelines or recommendations coming from T2 research into health practice. Especially for procedures such as susceptibility testing, where genomic variants as a risk or a protective factor for developing a future disease can be identified, it is not known how the dissemination of knowledge as well as endorsement of implementation can be promoted. Thus, the key task of this phase is to analyse how knowledge is turned into action. T4 -From health practice to health impact: T4 seeks to evaluate the 'real world' health outcomes of a genomic application in practice on population level. What are the health consequences of a technology or intervention within the population? These consequences not only include issues of value for money but also the analysis of patients' or populations' perspectives and preferences. Does the technology do more good than harm?
One of the aims of the PHGEN project was to identify how the translational research process can be assisted by traditional public health instruments. A working group was focussed on assessment approaches in public health, like health technology assessment (HTA), health needs assessment (HNA) and health impact assessment (HIA) and their contribution to the translation of genome-based health applications. Based on the experiences of the working group, a narrative review was carried out to characterise and identify practical examples of these instruments. The review focussed on research articles, textbooks and 'grey' literature, e.g. reports resulting from EU-subsidised projects or from European agencies. As a second step, these 3 techniques were 'mapped' in terms of their contribution to the T1-T4 phases of the continuum of translational research in genomic medicine. This exercise entails a judgement on the scope (in terms of aspects covered) of each instrument.
Health Technology Assessment
HTA can be seen as a bridge between the world of research and the world of decision making, in particular policy making [12] . HTA is described by the European Network of Health Technology Assessment (EUnetHTA) as '… a multidisciplinary process that summarises information about the medical, social, economic and ethical issues related to the use of a health technology in a systematic, transparent, unbiased, robust manner. Its aim is to inform the formulation of safe, effective, health policies that are patient focused and seek to achieve best value. Despite its policy goals, HTA must always be firmly rooted in research and the scientific method' [13] .
The term 'technology' within HTA can be understood broadly. Besides 'hardware' technologies like drugs, medical devices or diagnostic tests, HTA also analyses softer technologies like methods used in health promotion or primary prevention. HTA is in most cases technologyorientated, but also problem-or project-orientated assessments exist [14] . HTA has spread throughout the world and international collaboration is growing steadily.
It has long been recognised that, ideally, assessments should be done in phase with the life cycle of a technology, which is often described having 5 stages [15] . During the first phase, one can think of technologies under development. The second stage refers to technologies prior to adoption. The third stage covers technologies in the phase of adoption. The fourth stage is when technologies are widely used. In the fifth and final stage, the technology has become old-fashioned and should be abandoned. One speaks of future, emerging, new, accepted, and obsolete technologies, respectively.
The process of HTA may be viewed as an interdependent and nondiscrete flow of 6 types of actions: (1) identification of new health technologies; (2) priority setting, selecting those technologies most in need of assessment; (3) testing, conducting the appropriate data collection and analysis; (4) synthesis, collecting and interpreting existing information and the results of the testing step and, usually, making judgements and sometimes recommendations about appropriate use; (5) dissemination, providing the synthesized information, or any other relevant information, to the appropriate persons who use or make decisions concerning the use of health technologies; (6) implementation, securing that changes in knowledge and attitudes result in changes in behaviour or in particular decisions. Finally, in addition to the stages mentioned above, the study of the diffusion of health technologies in health care systems has been a long-standing tradition in health technology assessment [16] .
The Role of HTA for Translational Research in Genomic Medicine
The development of HTA is mainly influenced by methodological streams of policy analysis, evidencebased medicine, health economic evaluation, and social and humanistic sciences [17] . Therefore, the process of translational research (T1-T4) [4] is covered to the broadest extent by different combinations of HTA methods and approaches.
In the process of HTA, the activity of horizon scanning aims at identifying relevant emerging and new health technologies, thereby contributing to promote the adoption of beneficial and cost-effective technologies and to prevent the undesirable consequences of the unorganised haphazard introduction of high-impact technologies [18] . The concepts of early identification have gained considerable support and about a third of all HTA agencies worldwide have established a horizon scanning system. Since 1997, several agencies are collaborating in Euro Scan, an international network for exchange of in-formation and evaluation of new health technologies [19] . A few years ago, results of a horizon scanning exercise focusing on genetic tests has been published, showing that there are yet only a limited number of clinical applications, predominantly in oncology and cardiovascular disease [20] .
Systematic literature reviews and quality assessment of published research are at the core of HTA and evidence-based medicine alike. HTA, in addition, takes into account ethical considerations, patients' aspects, organisational issues regarding the delivery of the technology and economic evaluations when formulating recommendations for policy making [21] . Furthermore, peer review plays a significant role in HTA to assure high quality and independence of the assessment. HTA is thus in a position to tackle translational research needs in T2-T4 where evidence-based guideline development, research on implementation, dissemination, and diffusion as well as outcome research becomes relevant.
Two Canadian research teams [22, 23] who work on HTA methodologies have contributed in particular to specific requirements for the assessment of genomebased technologies including genome-based health information. Giacomini et al. [22] developed a 'three-domain model' for technology assessment and coverage decision making regarding emerging genetic testing services in Ontario. The domains identified (1) criteria for decision making (e.g. intended purpose of the test, effectiveness, aggregated costs, demands, cost-effectiveness), (2) the definition of cut-off points for each criterion, and (3) guidance for conditional coverage decisions. Blancquaert et al. [24] also developed an innovative HTA framework applicable to genome-based health applications ( fig. 1 ) . The framework comprises a critical analysis of the evidence on the analytical and clinical validity of the technology, an assessment of the utility, acceptability and feasibility of the diagnostic and screening strategies as well as an organisational analysis of the technology's interaction with health care delivery and services. Ethical, legal and social issues are expected to emerge at all stages of the analysis and these considerations thus need to be integrated accordingly [23] . In addition, economic analysis can be performed for each dimension or globally [25] . Whereas HTA strives to capture all the available evidence whatever the stage in the lifecycle of the technology, the primary data accrue in phases and a parallel can be made between the T1 and T2 of the translational research process. The evaluation of the organisation of health care may be seen as a necessary step prior to T3, where clinical guidelines are transferred to health practice.
A limitation of the conventional HTA approach is that the dynamics of technology development are not taken into account. Technologies may change rapidly, be 'on the move' in a technological sense, and although HTA can accommodate this by iterative assessment, opportunities to actually 'shape' the technology and to channel research in the needed direction are hardly ever realised. Constructive technology assessment (CTA) has been advocated as a means to address this issue [26] . By acknowledging the socio-dynamic processes of technology development, CTA can influence the development and implementation of the technology. The foundations for these processes have to be laid in T1 of the translational research process, but could continue until the final stages. Close contacts between researchers, innovators and decision makers early in the process are a prerequisite for the success of the approach, guiding and steering the process according to the decision making needs of a specific group of clinicians and patients for instance. Diagnostic methods of CTA include among others traditional social sciences techniques and socio-technical mapping techniques to identify the past and possible future scenarios of technological dynamics.
Intervention methods in CTA include, for example, techniques like awareness initiatives, controlled experiColor version available online Fig. 1 . HTA framework for genetic tests [24] . mentation, consensus conferences, and dialogue workshops, to influence technological development and application [26] . Currently, CTA is regarded as complementary to HTA, with as yet relatively few applications in health care.
A study in the Netherlands may serve as an example of CTA where a socio-technical analysis of preconceptional carrier screening for cystic fibrosis and haemoglobinopathies was carried out to elucidate the preconditions for successful implementation [27] .
HTA is currently used in the translational process in many countries, and international expert networks exist to develop HTA further. So experts and infrastructure are already present, and in some cases, genome-based technologies have already been added to their agenda. Additionally to the fact that this HTA framework encompasses dimensions of genetic test evaluation, as described by ACCE (and beyond), it has a clear policy orientation. Thus, decision making can be grounded on a more informed level; it reduces the amount of uncertainty, and it can specify the conditions for the use and the implementation of new technologies [23] . HTA thus builds the basis for the effective and efficient implementation and diffusion of a proven technology and supports research, since evidence is needed to formulate specific recommendations and support the decision making process in the field of genomics.
Health Needs Assessment
HNA is used as an objective and evidence-based method of tailoring health services. HNA aims to match the specific health needs of people to benefit population health. HNA also addresses health inequalities and identifies (1) nonrecipients of beneficial health interventions, (2) recipients of ineffective health care, (3) recipients of inefficient health care, and (4) recipients of inappropriate health care [28] .
Thus, health needs can be understood as issues that would benefit from changes in health care or from wider social and environmental changes [29] . HNA is defined as '… a systematic method of reviewing the health issues facing a population, leading to agreed priorities and resource allocation that will improve health and reduce inequalities' [30] .
By conducting a HNA, patterns of disease in the (local) population and regional differences in health are described. HNA uses epidemiological, qualitative and comparative methods to describe health problems, to identify inequalities in health and access to services, and to determine priorities for the most effective development or use of services. Timely and accurate information is essential if health services are to meet the changing and different health needs of their populations, subpopulations and individuals. Routine health information can provide data for epidemiologically based assessments of ill health and help target what health services are needed. Alternatively, the burden of disease can be represented by summary measures of population health such as disability adjusted life years (DALYs), which can be used to identify current and future health needs and plan essential health services.
HNA's objective is to influence policy, to enhance interagency collaboration, to promote research and the development of priorities as well as to support rational decision making [29] . To achieve this aim, HNA is carried out in 2 steps: (1) the estimation of the frequency of various health problems in a population, and (2) the examination of the evidence for the beneficial and harmful effects of the interventions targeted at each health problem [31] .
The Role of HNA for Translational Research in Genomic Medicine
As HNA aims to identify the health needs of a local population, it supports translational research with tools for prioritisation and identification of areas for needed professional and service development as well as needed requirements of genome-based health applications. Furthermore, education and training needs can be identified for those who are going to apply genome-based health applications [32] as well as for the population (health literacy). As Wright et al. [29] argue, HNA should not only describe the greatest burden of disease in a given population and that by '(i)ncorporating the concept of a capacity to benefit (HNA) introduces the importance of the effectiveness of health interventions and attempts to make explicit what benefits are being pursued'. Therefore, HNA ideally seems to support T2-T3 translational research by identifying requirements for the best possible implementation of the genome-based health application or by identifying technologies which are needed most. Despite this HNA might be applicable in T4 research to identify if the application is equally provided in the population, if it is effective or if there are subpopulations in which needs are unmet or over met. By using epidemiological health monitoring data, it can be assessed if the distribution of disease incidence, prevalence, mortality, or health-related quality of life has changed af-ter implementation of the application and if there are differences between subpopulations.
In more general terms, HNA may be used to support T2-T4 research in terms of identifying priority areas of genomic health innovations in disease prevention and health care as well as to identify infrastructural needs and to evaluate the use of the application and refine the needs assessment. Questions which can be answered by a HNA are [30] : (1) Impact -which health conditions and determinants have the highest impact on the health functioning of the population? (2) Changeability -can the most significant health conditions and determinants be changed effectively? (3) Acceptability -what are the most acceptable changes needed to achieve the maximum impact? (4) Resource feasibility -are there adequate resources available to make the required changes?
According to phase T3 the answers to the questions of acceptability and resource feasibility are the most informative for the implementation of genome-based health applications, assuming that the innovation meets the priority needs of the population.
Health Impact Assessment
HIA aims to identify the potential health consequences of a policy on a given population, including the positive health outcomes as well as potential adverse effects on health and health inequalities [33] , and to give recommendations on how the positive health effects may be enhanced and the adverse effects may be reduced. Indirectly, HIA has its legal basis at the European level in the Amsterdam treaty which states that 'a high level of human health protection shall be ensured in the definition and implementation of all Community policies and activities' (Article 152) [34] . In the Gothenburg consensus HIA is defined as 'a combination of procedures, methods and tools by which a policy, a program or project may be judged as to its potential effects on the health of a population and the distribution of effects within a population' [35] .
HIA is typically used to predict a priori the health consequences of a policy, a programme or a project (prospective HIA) for a given population, but it is also carried out retrospectively or concurrently. An important feature of HIA is that the policies under scrutiny do not necessarily have health as their primary objective (see also the concept of 'Health in All Policies' [36] ), since health is not only affected by biological and lifestyle factors but also by social and community networks, living and working conditions as well as by general socio-economic, cultural and environmental conditions [37] . HIA can be used to assess policies on local, regional, national, or supra-national level [38] . Thereby, HIA strives to influence decision making by raising awareness of the relationship between health and physical, social, and economic environments, by producing estimates of the impact of a variety of de cisions on the health of the population, and by supporting stakeholder participation, including that of lay people. Methodologically speaking, HIAs can be based on a participative approach or on expert opinions; they can be qualitative, quantitative or a mixture of both [39] .
The HIA approach includes chronologically the following processes: screening (identifying policies which could have an impact on health), scoping (identifying the direct and indirect health effects to be considered), assessment in terms of risks and benefits (identifying the populations which can be affected and how), reporting (presentation of the results to the decision makers), and monitoring/evaluation of consequences of implementation.
The Role of HIA for Translational Research in Genomic Medicine
HIA can be used to anticipate consequences that may occur when introducing genome-based technologies for public health purposes. Therefore, HIA should be conducted early in the policy making process. It can be supportive of the translational research process to preestimate the health impact which should, according to the translational research model, be confirmed by outcomes research in phase T4 (from practice to health impact). HIA would thus provide a systematic approach for establishing a scenario which can provide insight in the implementation phase at an earlier stage. So the dissemination, implementation, and diffusion of the genome-based health applications or programs can be developed more constructively and missing knowledge or research needs can be identified earlier.
Furthermore, HIA focuses on the consequences of policies or programmes for health and disease in the population and takes general ethical, legal and social implications into account. Within HIA, it is aimed to describe implications not only for the health care sector but also for other related areas, e.g. the impact of the routine production and delivery of the technology on the labour force or the impact of the results of the application at the individual and social level. HIA also identifies require-ments which are needed when introducing the application, for example at the policy level. This might be e.g. changes in regulations on data protection or other regulatory efforts that can be based on laws, on the regulation by commissioners and payers or on professional regulation (e.g. practice guidelines) [40] . In a nutshell, HIA can be used to make decision makers aware of the whole breadth of implications of policies or technologies including areas of uncertainty [41] .
Summary
To capture the supportive features of HTA, HNA and HIA, figure 2 shows the contribution of each to the continuum of translational research in genomic medicine and the methods or tasks of each assessment which are relevant in T1-T4. The right hand column indicates which instruments have a wider scope and go beyond the objectives of T1-T4 research.
As illustrated, HTA (in combination with CTA) delivers the most comprehensive methodologies. HNA focuses on the needs of the population and the health system which come up when introducing new technologies or health programmes and supports the identification of relevant technologies (T1). When genome-based health applications are implemented, HNA can be used to redefine the use of the application by analysing the effects on population health. Also, HNA supports T2-T3 research by identifying gaps which need to be overcome when one wants to identify and increase the feasibility and acceptance of a new health technology in the population. An early estimation of the effects of a new application and a more general view would be added by HIA which thereby would support phase T3-T4. The goals of HTA, HNA and HIA extend beyond the scope of T1-T4. HTA includes, for example, horizon scanning and early identification of relevant technologies. In the same vein, HNA may help to identify relevant areas of public health where genome-based health information might be most needed and supportive. Adding the approach of constructive technology assessment (CTA), a new dimension comes in that extends phase T1 and T2 translational research by assessing the impact of a new technology in a broader manner at an early stage and thereby shaping the design of further analysis, the development and the implementation of the technology [42] . As with the HIA approach, the impact of the technology is anticipated. Moreover, neither CTA nor HIA focus exclusively on health, but rather include the wider social and legal aspects of the technology. With the involvement of different stakeholders and by means of an objective assessment, HIA can help resolve social conflicts between opposing views on a policy or programme [36] .
Discussion and Conclusion
Assessments in PHG, one of the key and most challenging tasks in this field, relies on scientific approaches to assess the impact of discovered genomic variants linked to different health outcomes in individuals, communities and populations [43] . The paper describes existing methodologies in public health and points out their supportive nature for the continuum of translational research in genomic medicine. Several methodologies exist which assess technologies, needs and impacts on health on a population level.
HTA (and CTA), HNA and HIA each have their specific main focus, but despite different backgrounds, there are overlaps in terms of methodologies, procedures and aims. What they have in common is the potential to inform and further the public dialogue and participation, in an era of novelty and scarce awareness of the consequences and possibilities of genome-based science and technologies [44] .
As mentioned in the introduction, the European Commission urges that new technologies be evaluated properly, including issues of cost-effectiveness, equity, the need for additional training by health professionals, and organisational implications, for example capacity planning [1] . The description of HTA, HNA and HIA shows that all of these issues are covered by one or more of the existing methodologies used in public health. Furthermore, HNA, HTA and HIA deliver facilitating components for all of the translational research phases (T1-T4) and sometimes go beyond these defined translational needs, especially with regard to policy translation (definition of goals, requirements, planning steps, support by the formulation of programmes and reforms, evaluation, and refinement of health programmes and other interventions). Moreover, HTA, HNA and HIA promote scientific, policy and public debate as they tackle issues of relevance to citizens.
The most complete set of methods is probably provided through HTA (and CTA), but also the other methodologies can support the translation from bench to bedside not only for health practitioners but also for the public health community and decision makers.
Given a high number of PHG technologies on the horizon, priorities will need to be set for assessment using criteria that may be adapted to the technology at hand [45] . To accompany timely identification with timely assessment in the face of considerable uncertainty, a number of analytical techniques can be employed, e.g. rapid HTA, rapid systematic reviews, mini-HTA [46] , etc. Since these assessment tools are already more or less integrated in the health systems of most European member states as well as internationally, the political and social relevance and impact of these methodologies will be high. The proposed instruments are oriented towards change in policy and practice. We therefore believe that these assessment tools offer an appropriate and useful systematic framework for translational research and assessment in the field of public health genomics, and we expect in the future to see more academic interaction between the respective fields. Clearly, there is a strong need for further development, and the specificities of novel genome-based knowledge may require some adaptation. We recommend starting a discourse between researchers in genomic science and practitioners in HTA, HNA and HIA to explore possibilities for cooperation to enhance the translation of genome-based health applications for public health practice. It can be expected that the discussion will be brought forward by the follow-up project PHGEN II which aims to develop best practice guidelines for public health genomics which also cover the use of HTA, HNA and HIA for translational research.
